Transfusion Stem Cell Progenitor Cells

In the Administration section, at table 302, Circulatory body system, Transfusion, a new substance value has been added for Hematopoietic Stem/Progenitor Cells, Genetically Modified. Body System Approach Function/Device Qualifier 3 Peripheral Vein 4 Central Vein 0 Open 3 Percutaneous C Hematopoietic Stem/Progenitor Cells, Genetically Modified 0 Autologous The new codes will allow the reporting of the administration of genetically modified hematopoietic stem cell treatments, including based gene therapies such as OTL-101. OTL-101, the first ex vivo autologous CD34+ hematopoietic stem cell progenitor cells (HSPC) based gene therapy (HSPC-GT) available for use in the US, is intended for the treatment...

Subscribe or sign in to view the full article.

articles:   
Note:  The following article synopsis was NOT provided by the AHA. It was created by Find-A-Code/innoviHealth.

Article Overview

This article covers a coding update in the ICD-10-PCS Administration section involving transfusion of genetically modified hematopoietic stem/progenitor cells. It also provides clinical background on an autologous gene therapy approach, the disease context it is associated with, and the general treatment process involved. The content is relevant to coding professionals, HIM staff, and others tracking procedure coding changes for cell-based and gene therapy services.

Why This Topic Matters

Coding updates for advanced cell and gene therapies can affect procedure reporting, data capture, and compliance. Understanding the scope of the change helps coders and clinical documentation teams recognize when the new administration category may be relevant.

Article Sections

  1. ICD-10-PCS Administration Update

    Introduces a new substance value in the Administration section and places it within the broader structure of the procedure coding system. The section frames the change in terms of transfusion-related reporting.

  2. Clinical and Treatment Background

    Summarizes the therapy context, including the type of cell-based treatment discussed, the associated rare disorder, and the general treatment workflow. It also outlines the patient population and the clinical setting in which the therapy is used.

What You Will Learn

  • The general purpose of the procedure coding update
  • How the article situates the update within a cell and gene therapy context
  • The clinical background associated with the treatment referenced in the article
  • Why transfusion reporting for advanced therapies may need special attention

Who Should Read This

  • Medical coders
  • HIM professionals
  • Clinical documentation specialists
  • Revenue cycle staff
  • Compliance teams

Subscribe or sign in to view the full article.

articles:   
  • The official AHA publication for ICD-10-CM and ICD-10-PCS coding guidelines and advice
  • Current newsletters added each quarter
  • Full Archives - over 3100 articles
  • ALL years/issues back to 1984 organized by year and issue
  • Includes ICD-10-CM/PCS Articles since 2013
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles
  • View all the articles associated with any code, right from the code page!
Access to this feature is available in the following products:
  • AHA's Coding Clinic® - ICD-10-CM/PCS +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.

Aimee- AI -powered coding assistant - Try it now for Free Would you like Aimee - AI
to help you with this?